efficacy of topiramate as add-on therapy in two different types of progressive myoclonic epilepsy
Clicks: 120
ID: 256663
2013
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
30.0
/100
120 views
19 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #31 of 33 articles by views in journal of the brazilian chemical society
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
The present article describes two unrelated cases of progressive myoclonic epilepsy (PME) of the Lafora’s disease and Unverricht-Lundborg types who were treated with topiramate (TPM) as add-on therapy for their myoclonus. After the initiation of topiramate therapy both cases responded with marked decrease in myoclonic seizure frequency and improvement of quality of life. Topiramate appears to be a useful alternative agent in cases of PME and could be consider for adjunctive therapy.
| Reference Key |
demir2013actaefficacy
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Caner Feyzi Demir;Hasan Hüseyin Özdemir;Bülent Müngen |
| Journal | journal of the brazilian chemical society |
| Year | 2013 |
| DOI |
10.14712/18059694.2014.37
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.